Global Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno-Associated, Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others), By Grade (GMP Grade and R&D Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics, and Marketed Therapeutics) By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 635.1 Mn in 2021 and is expected to exhibit a CAGR of 23.2% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Increasing number of patients opting for gene therapy is expected to drive the global plasmid DNA manufacturing market growth over the forecast period. For instance, according to the data published by the Journal of Gene Medicine: March 2018, till November 2017, an estimated 2,600 gene therapy clinical trials were either ongoing, completed, or have been approved in 36 countries. Countries where the trials were conducted include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, severe combined immunodeficiency (SCID), ocular diseases, neurological diseases, and others.
Global Plasmid DNA Manufacturing Market – Impact of Coronavirus (COVID-19) Pandemic on Clinical Trials and Drug Development
Number of COVID-19 infections have been rising globally, with this the apprehension regarding the shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. Moreover, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients who may require critical care. Currently, there is an urgent need in the rapid acceleration of the manufacturing process to develop a wide range of test-kits (antibody tests, self-administered, and others). Key players operating in the market are focusing on the development of DNA vaccines for the treatment of COVID-19. In April 2020, INOVIO pharmaceuticals Inc. entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, which is currently in Phase 1 clinical testing in the U.S. for COVID-19 treatment and could potentially advance to Phase 2/3 efficacy trials this summer April 2020. Increasing government initiatives to combat COVID-19 will help recover the pandemic situation early. For instance, in March 2020, the U.S. announced a US$ 2.9 million assistance package for India to help the Indian government prepare laboratory systems, activate case-finding and event-based surveillance, and support technical experts for response and preparedness. This is a part of the U.S. global assistance initiative to fight COVID -19.
Browse 44 Market Data Tables and 46 Figures spread through 266 Pages and in-depth TOC on “Global Plasmid DNA Manufacturing Market ”- Forecast to 2028, Global Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno Associated, and Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others), By Grade (GMP Grade and R&D Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), By Development Phase (Pre- Clinical Therapeutics, Clinical Therapeutics, and Marketed Therapeutics) By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Key players are focusing on various inorganic growth strategies such as collaborations, this is expected to boost the growth of the Global Plasmid DNA Manufacturing Market over the forecast period. For instance, in May 2018, Biomay, CDMO and BIA Separations, a leading biochromatography development and manufacturing company, entered into a collaboration agreement in order to co-develop an economical production system for the production and purification of large DNA plasmids.
Key Takeaways of the Global Plasmid DNA Manufacturing Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.